Balyasny Asset Management LLC Ardelyx, Inc. Transaction History

Balyasny Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$3.3 - $4.83 $217,710 - $318,649	65,973 New	65,973 $269,000
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $313,897 - $561,033	117,126 Added 353.74%	150,237 $719,000
Q4 2022 Feb 14, 2023	BUY	$1.22 - $2.85 $40,395 - $94,366	33,111 New	33,111 $94,000
Q2 2022 Aug 15, 2022	BUY	$0.51 - $1.17 $9,709 - $22,275	19,039 New	19,039 $11,000
Q3 2018 Nov 14, 2018	SELL	$3.75 - $4.65 $168,761 - $209,263	-45,003 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $45,880 - $71,920	12,400 Added 38.03%	45,003 $167,000
Q1 2018 May 15, 2018	BUY	$5.05 - $7.9 $25,250 - $39,500	5,000 Added 18.11%	32,603 $165,000
Q4 2017 Feb 14, 2018	BUY	$4.85 - $7.8 $20,001 - $32,167	4,124 Added 17.56%	27,603 $182,000
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.7 $102,133 - $133,830	23,479	23,479 $131,000

218

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $801M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.